230 related articles for article (PubMed ID: 35925450)
21. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S
J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
[TBL] [Abstract][Full Text] [Related]
22. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
[TBL] [Abstract][Full Text] [Related]
23. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease.
Yanagimoto K; Nomura Y; Masuda K; Hirabayashi M; Morita Y; Yoshishige M; Ueno K; Eguchi T; Kawano Y
Int Arch Allergy Immunol; 2014; 164(2):83-8. PubMed ID: 24903098
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
[TBL] [Abstract][Full Text] [Related]
25. Clinical Features of Kawasaki Disease With Atlantoaxial Rotatory Fixation.
Michihata N; Suzuki T; Honda A; Oka I; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
Pediatr Infect Dis J; 2022 Aug; 41(8):626-630. PubMed ID: 35544743
[TBL] [Abstract][Full Text] [Related]
26. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
Manlhiot C; Yeung RS; Chahal N; McCrindle BW
Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
[TBL] [Abstract][Full Text] [Related]
27. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
[TBL] [Abstract][Full Text] [Related]
28. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
[TBL] [Abstract][Full Text] [Related]
29. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
30. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
[TBL] [Abstract][Full Text] [Related]
31. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
Miyata K; Miura M; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H
Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007191. PubMed ID: 33541111
[TBL] [Abstract][Full Text] [Related]
34. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease.
Jaggi P; Wang W; Dvorchik I; Printz B; Berry E; Kovalchin JP; Texter K; Ramilo O; Burns JC; Tremoulet AH
Pediatr Infect Dis J; 2015 Dec; 34(12):1315-8. PubMed ID: 26353031
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety associated with the infusion speed of intravenous immunoglobulin for the treatment of Kawasaki disease: a randomized controlled trial.
Fukui S; Seki M; Minami T; Kotani K; Oka K; Yokomizo A; Matsubara D; Sato T; Nozaki Y; Saito M; Kikuchi Y; Miyamoto K; Monden Y; Yamagata T
Pediatr Rheumatol Online J; 2021 Jul; 19(1):107. PubMed ID: 34217297
[TBL] [Abstract][Full Text] [Related]
36. First-line corticosteroids for Kawasaki disease: Pulse versus multiple dose.
Abrams JY; Ae R; Maddox RA; Schonberger LB; Nakamura Y; Belay ED
Pediatr Int; 2022 Jan; 64(1):e15112. PubMed ID: 35468260
[TBL] [Abstract][Full Text] [Related]
37. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
[TBL] [Abstract][Full Text] [Related]
38. Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease.
Li W; Zhang L; Wang Z; He X; Lin H; Wang Y; Yuan J; Xie X; Zhang X; Qin Y; Huang P
Int J Clin Pract; 2022; 2022():2726686. PubMed ID: 35989868
[TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin for the treatment of Kawasaki disease in children.
Oates-Whitehead RM; Baumer JH; Haines L; Love S; Maconochie IK; Gupta A; Roman K; Dua JS; Flynn I
Cochrane Database Syst Rev; 2003; 2003(4):CD004000. PubMed ID: 14584002
[TBL] [Abstract][Full Text] [Related]
40. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events.
Miura M; Kobayashi T; Kaneko T; Ayusawa M; Fukazawa R; Fukushima N; Fuse S; Hamaoka K; Hirono K; Kato T; Mitani Y; Sato S; Shimoyama S; Shiono J; Suda K; Suzuki H; Maeda J; Waki K; ; Kato H; Saji T; Yamagishi H; Ozeki A; Tomotsune M; Yoshida M; Akazawa Y; Aso K; Doi S; Fukasawa Y; Furuno K; Hayabuchi Y; Hayashi M; Honda T; Horita N; Ikeda K; Ishii M; Iwashima S; Kamada M; Kaneko M; Katyama H; Kawamura Y; Kitagawa A; Komori A; Kuraishi K; Masuda H; Matsuda S; Matsuzaki S; Mii S; Miyamoto T; Moritou Y; Motoki N; Nagumo K; Nakamura T; Nishihara E; Nomura Y; Ogata S; Ohashi H; Okumura K; Omori D; Sano T; Suganuma E; Takahashi T; Takatsuki S; Takeda A; Terai M; Toyono M; Watanabe K; Watanabe M; Yamamoto M; Yamamura K
JAMA Pediatr; 2018 May; 172(5):e180030. PubMed ID: 29507955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
